Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.

Burmester GR, Strand V, Rubbert-Roth A, Amital H, Raskina T, Gómez-Centeno A, Pena-Rossi C, Gervitz L, Thangavelu K, St John G, Boklage S, Genovese MC.

RMD Open. 2019 Oct 18;5(2):e001017. doi: 10.1136/rmdopen-2019-001017. eCollection 2019.

2.

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.

Genovese MC, van der Heijde D, Lin Y, St John G, Wang S, van Hoogstraten H, Gómez-Reino JJ, Kivitz A, Maldonado-Cocco JA, Seriolo B, Stanislav M, Burmester GR.

RMD Open. 2019 Aug 1;5(2):e000887. doi: 10.1136/rmdopen-2018-000887. eCollection 2019.

3.

Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.

Fleischmann R, Genovese MC, Lin Y, St John G, van der Heijde D, Wang S, Gomez-Reino JJ, Maldonado-Cocco JA, Stanislav M, Kivitz AJ, Burmester GR.

Rheumatology (Oxford). 2020 Feb 1;59(2):292-302. doi: 10.1093/rheumatology/kez265.

PMID:
31312844
4.

Mycobacterium tuberculosis expresses methionine sulphoxide reductases A and B that protect from killing by nitrite and hypochlorite.

Lee WL, Gold B, Darby C, Brot N, Jiang X, de Carvalho LP, Wellner D, St John G, Jacobs WR Jr, Nathan C.

Mol Microbiol. 2009 Feb;71(3):583-93. doi: 10.1111/j.1365-2958.2008.06548.x.

5.

Peptide methionine sulfoxide reductase: structure, mechanism of action, and biological function.

Weissbach H, Etienne F, Hoshi T, Heinemann SH, Lowther WT, Matthews B, St John G, Nathan C, Brot N.

Arch Biochem Biophys. 2002 Jan 15;397(2):172-8. Review.

PMID:
11795868
6.

Peptide methionine sulfoxide reductase from Escherichia coli and Mycobacterium tuberculosis protects bacteria against oxidative damage from reactive nitrogen intermediates.

St John G, Brot N, Ruan J, Erdjument-Bromage H, Tempst P, Weissbach H, Nathan C.

Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9901-6. Epub 2001 Jul 31.

7.
8.
9.

Thrombolytic therapy in patients with an abnormality of blood coagulation.

St John G, Talley JD.

J Ark Med Soc. 1995 Jul;92(2):81-2. No abstract available.

PMID:
7642479
10.

Safe administration of iron dextran to a patient who reacted to the test dose.

Monaghan MS, Glasco G, St John G, Bradsher RW, Olsen KM.

South Med J. 1994 Oct;87(10):1010-2.

PMID:
7939912
11.

Identification of nitric oxide (NO) in human blood.

Freeman G, Dyer RL, Juhos LT, St John GA, Anbar M.

Arch Environ Health. 1978 Jan-Feb;33(1):19-23.

PMID:
415669
12.

Determination of the concentration of explosives in air by isotope dilution analysis.

St John GA, McReynolds JH, Blucher WG, Scott AC, Anbar M.

Forensic Sci. 1975 Aug-Oct;6(1-2):53-66.

PMID:
814074
13.

Organic polymeric polyphosphonates as potential preventive agents of dental caries: in vivo experiments.

Anbar M, St John GA, Elward TE.

J Dent Res. 1974 Sep-Oct;53(5):1240-4. No abstract available.

PMID:
4529333
14.

Organic polymeric polyphosphonates as potential preventive agents of dental caries: in vitro experiments.

Anbar M, St John GA, Scott AC.

J Dent Res. 1974 Jul-Aug;53(4):867-78. No abstract available.

PMID:
4526378
15.

Fate and toxicity of orally administered polyethylene polyphosphonates.

Anbar M, Newell GW, St John GA.

Food Cosmet Toxicol. 1973 Dec;11(6):1001-10. No abstract available.

PMID:
4783990
16.

Adsorption of polyphosphonated polyethylene on enamel of teeth.

Anbar M, St John GA.

J Dent Res. 1971 May-Jun;50(3):778. No abstract available.

PMID:
5280591

Supplemental Content

Loading ...
Support Center